Data for the paper: ‘Effects of different factors on the efficacy of anti PD-(L)1 monotherapy in patients with advanced non-small cell lung cancer: An observational, retrospective cohort study’
doi: 10.4121/19606378
![cc-by-nc-sa.png logo](/static/images/licenses/cc-by-nc-sa.png)
Effects of sex, age, EGFR mutation status and smoking status on immunotherapy. we showed that the benefits for PFS and OS were similar in male and female, and in younger (< 65 years of age) and older (≥65 years of age) patients. EGFR mutation status and smoking status are two independent influencing factors. Regardless of EGFR mutation status, the ORR and PFS of current-smokers were better than those of never-smokers; The benefits of immunotherapy for other mutant subtypes except 19del, L858R and T790M were similar to those of EGFR wild-type; Former-smokers are a unique population who benefit poor from immunotherapy than never-smokers or current-smokers.
- 2022-04-20 first online, published, posted
- This work was supported by grants B2021348 from the Guangdong Medical Research Foundation and 1202101004 from the President Foundation of Integrated Hospital of Traditional Chinese Medicine, Southern Medical University.
DATA
-
233,100 bytesMD5:
c89cc5428f1f46cecb4eccd2d033d2b8
Figure 1 Case inclusion process.pdf -
2,134,571 bytesMD5:
076943bf5e1fbfea99a6d8e7c8451f61
Figure2.A-J.pdf -
2,179,481 bytesMD5:
7af6ded3ac5dccf6eebb53fa1eaa90ab
Figure3.A-D.pdf -
12,253 bytesMD5:
8ac704be316743791578c29a3aefb776
Table 1- Baseline Characteristics.xlsx -
12,228 bytesMD5:
ddc570b47d86a1bace0f9b597811c548
Table 2- Univariable and Multivariable Analysis.xlsx -
11,002 bytesMD5:
3e9fdf0f28f4235f2b76b48ff130bdf0
Table 3- Clinical benefit.xlsx - download all files (zip)
4,582,635 bytes unzipped